Preventive treatment for latent tuberculosis infection

Filiz Duyar Ağca (Ankara, Turkey), Filiz Duyar Agca, Onur Aksu Ceyhan

Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis
Session: Epidemiological insights into tuberculosis pathogenesis
Session type: Thematic Poster
Number: 2744
Disease area: Paediatric lung diseases, Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Filiz Duyar Ağca (Ankara, Turkey), Filiz Duyar Agca, Onur Aksu Ceyhan. Preventive treatment for latent tuberculosis infection. Eur Respir J 2016; 48: Suppl. 60, 2744

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A novel nurse-led approach improves treatment completion rates for latent tuberculosis infection (LTBI) treatment
Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches
Year: 2014



Liver injury in treatment of latent tuberculosis infection - is the age cut-off for treatment justified?
Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches
Year: 2014


Latent TB infection: Patient choices and completion of treatment
Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics
Year: 2016


Do we need to screen for latent TB when initiating a methotrexate treatment?
Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment
Year: 2013

The effectiveness of programmatic management of latent tuberculosis infection in the Netherlands
Source: International Congress 2015 – Latent TB infection and screening
Year: 2015


Social determinants of drug-susceptible and drug resistant tuberculosis
Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis
Year: 2016

Delay in pulmonary tuberculosis treatment in Croatia
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013

Is there a need for prolonged follow up in mono-drug resistant TB?
Source: International Congress 2014 – Tuberculosis: epidemiology and public health
Year: 2014


Prevalence of latent tuberculosis infection among household contacts and community controls in South India
Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment
Year: 2013


High prevalence of hepatitis C among patients with drug-resistant tuberculosis and its impact on the treatment outcome in Azerbaijan prisons
Source: International Congress 2015 – Screening strategies in TB
Year: 2015

Characteristics of tuberculosis (TB) in patients that died from TB in Poland
Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis
Year: 2016


Impact and management of TB childhood outbreaks in EU/EEA
Source: Annual Congress 2013 –Epidemiological and public health features of tuberculosis
Year: 2013

Public health guidance on programmatic management of latent tuberculosis infection in the European Union/European Economic Area
Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection I
Year: 2019



The causes of death among patients with tuberculosis
Source: International Congress 2015 – Epidemiology of TB: deaths, co-morbidities, migration and children
Year: 2015

The incidence of MDR-TB in new and retreatment cases of HIV and pulmonary tuberculosis co-infection
Source: Annual Congress 2013 –Tuberculosis: clinical aspects
Year: 2013


Monitoring latent tuberculosis infection diagnosis and management in the Netherlands
Source: Eur Respir J 2016; 47:1492-1501
Year: 2016



Prevention of TB in areas of high incidence
Source: Eur Respir Mon 2012; 58: 84-94
Year: 2012


Recurrent TB in Ireland is predominantly due to relapsed infection and is frequently associated with poor compliance with therapy
Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe
Year: 2016

Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016

Factors associated with pulmonary tuberculosis treatment outcome in Kocaeli; Turkey
Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1
Year: 2014